Categories: News

Harpoon Therapeutics to Host Pipeline Update Call and Webcast on December 13, 2021

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review the clinical status and provide an update on its pipeline programs.

The live call/webcast will take place at 4:30 p.m. ET / 1:30 p.m. PT on December 13, 2021 and can be accessed by dialing (866) 951-6894 for domestic callers and (409) 216-0624 for international callers with conference ID code number 2760075. A webcast of the live call will be available online in the investor relations section of the Harpoon website at www.harpoontx.com. A replay of the webcast will be available shortly after the live event and can be accessed at the same weblink.

About Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. The company’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

Contacts:

Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
media@harpoontx.com

Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com

Staff

Recent Posts

Cutera® Appoints Jeryl L. Hilleman to Board of Directors

Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of DirectorsBRISBANE, Calif.--(BUSINESS…

2 hours ago

GE HealthCare Announces Changes in Strategic Leadership and Key Segments to Better Serve Patients and Customers

Roland Rott, the current president and CEO of Ultrasound, will lead Imaging, replacing Jan Makela…

2 hours ago

Glass Lens Market size is set to grow by USD 7.36 billion from 2024-2028, Rising elderly population boost the market, Technavio

NEW YORK, June 10, 2024 /PRNewswire/ -- The global glass lens market size is estimated to grow…

2 hours ago

GT Independence Expands Senior Leadership Team

Company appoints Pearl Barnett as Chief Operating Officer; Megan Owen becomes Chief Compliance Officer STURGIS,…

2 hours ago

Anne Bink, Former FEMA Official, Joins IEM

MORRISVILLE, N.C., June 10, 2024 /PRNewswire/ -- IEM International, Inc., a global leader in emergency…

2 hours ago